International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(3):232-240.

Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
Mohammad Faizan Zahid, Umair Arshad Malik, Momena Sohail, Irfan Nazir Hassan, Sara Ali, Muhammad Hamza Saad Shaukat

Abstract


Karyotype is one of the main constituents of the International Prognostic Scoring System (IPSS) and revised-IPSS that are the cornerstones for the prognostication of patients with myelodysplastic syndromes (MDS). Del(5q), –7/del(7q), +8 and –Y are among the most extensively studied cytogenetic abnormalities in MDS. The same applies for normal karyotype. There are hundreds of other rare cytogenetic abnormalities that have been reported in MDS, included but not limited to –X, 3q abnormalities, +13/del(13q), i(17q), +21/–21. However, due to a very low number of patients, their impact on the prognosis of MDS is limited. Knowledge of the molecular consequences of different cytogenetic abnormalities allows us to modify treatment regimens based on drugs most active against the specific karyotype present, allowing for the opportunity to individualize MDS treatment and improve patient care and prognosis.


Keywords


Cytogenetics, Karyotype, Myelodysplastic syndromes, Myelodysplasia, Chromosomal abnormalities

Full Text:

PDF

References


Brunning R, Orazi A, Germing U,et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. Myelodysplastic syndromes/neoplasms, overview; p. 88-93.

Lindsley RC, Ebert BL. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013;8:21-47.

Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.

Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3):1534-42.

Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J ClinOncol.2012;30(8):820-9.

Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9.

Pellagatti A, Boultwood J. The molecular pathogenesis of the myelodysplastic syndromes. Eur J Haematol. 2015;95(1):3-15.

Climent Mn. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol. 2000;108(2):346-56.

Giagounidis AAN, Germing U, Strupp C. Prognosis of patients with del (5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol. 2005;84(9):569-71.

Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J ClinOncol. 2001;19(5):1405-13.

Jädersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica. 2009;94(12):1762-6.

Möllgård L, Saft L, Treppendahl MB, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 2011;96(7):963-71.

Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities. Cancer. 2009;115(22):5202-9.

Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-88.

Adès L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009;113(17):3947-52.

Jerez A, Gondek LP, Jankowska AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J ClinOncol. 2012;30(12):1343-9.

Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-9.

Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117(9):2567-76.

Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med. 2010;16(1):59-66.

Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med. 2010;16(1):49-58.

Lane SW, Sykes SM, Al-Shahrour F, et al. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood. 2010;115(17):3489-97.

Giagounidis AAN, Kulasekararaj A, Germing U, et al. Long-term transfusion independence in del (5q) MDS patients who discontinue lenalidomide. Leukemia. 2012;26(4):855-8.

Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-76.

List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-65.

Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del (5q) myelodysplasia in remission. N Engl J Med. 2010;363(11):1025-37.

Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. 2004;104(5):1474-81.

Beau MM, Davis EM, Eisenbart JD, et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996;88(6):1930-5.

McNerney ME, Brown CD, Wang X, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 2013;121(6):975-83.

Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-27.

Heuser M, Yap DB, Leung M, et al. Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood. 2009;113(7):1432-43.

Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-506.

Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-6.

Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. JJClinOncol. 2011;29(15):1963-70.

Nilsson L, Åstrand-Grundström I, Anderson K, et al. Involvement and functional impairment of the CD34+ CD38− Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood. 2002;100(1):259-67.

Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood. 2007;109(6):2399-405.

Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood. 2005;106(3):841-51.

Bacher U, Schanz J, Braulke F, et al. Rare Cytogenetic Abnormalities in Myelodysplastic Syndromes. Mediterr J Hematol Infect Dis. 2015;7(1):e2015034.

United K. Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chromosomes Cancer. 1992;5:83-8.

Wong AK, Fang B, Zhang L, et al. Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome?Arch Pathol Lab Med. 2008;132(8):1329-32.

Holmes RI, Keating MJ, Cork A, et al. Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. Cancer Genet Cytogenet. 1985;17(3):269-78.

Abruzzese E, Rao PN, Slatkoff M, et al. Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. Cancer Genet Cytogenet. 1997;93(2):140-6.

Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-36.

Manola KN, Sambani C, Karakasis D, et al. Leukemias associated with Turner syndrome: report of three cases and review of the literature. Leuk Res. 2008;32(3):481-6.

Stone JF, Sandberg AA. Sex chromosome aneuploidy and aging. Mutat Res. 1995;338(1):107-13.

Soderholm J, Kobayashi H, Mathieu C, et al. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia.1997;11(3):352-8.

Laricchia-Robbio L, Fazzina R, Li D, et al. Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells. Mol Cell Biol. 2006;26(20):7658-66.

Laricchia-Robbio L, Premanand K, Rinaldi CR, et al. EVI1 Impairs myelopoiesis by deregulation of PU.1 function.Cancer Res. 2009;69(4):1633-42.

Senyuk V, Sinha KK, Li D, et al. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Cancer RES. 2007;67(12):5658-66.

Wanquet A, Prebet T, Berthon Cl, et al. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol. 2015;90(10):859-63.

Mesa RA, Hanson CA, Ketterling RP, et al. Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. Blood. 2009;113(5):1200-1.

Dohner H, Arthur DC, Ball ED, et al. Trisomy 13: a new recurring chromosome abnormality in acute leukemia. Blood. 1990;76(8):1614-21.

Silva FPG, Lind A, Brouwer-Mandema G, et al. Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica. 2007;92(8):1123-6.

Dicker F, Haferlach C, Kern W, et al. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood. 2007;110(4):1308-16.

Shih LY, Huang CF, Wang PN, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004;18(3):466-75.

Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009;113(5):1002-5.

Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. TherAdvHematol. 2014;5(3):65-77.

Boyer J. del(13q) in myeloid malignancies. Atlas Genet Cytogenet Oncol Haematol; 2002. p. 29-31.

Morris CM, Cochrane JM, Benjes SM, et al. Molecular definition of interstitial deletions of chromosome 13 in leukemic cells. Genes Chromosomes Cancer. 1991;3(6):455-60.

Heim S. Cytogenetic findings in primary and secondary MDS. Leukemia Res. 1992;16(1):43-6.

Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65.

Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168-78.

Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-65.

Van Dyke DL. -21 or monosomy 21 (solely). Atlas Genet Cytogenet Oncol Haematol 2003. p. 27-28.

Kanagal‐Shamanna R, Bueso‐Ramos CE, Barkoh B, et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer. 2012;118(11):2879-88.

McClure RF, Dewald GW, Hoyer JD, et al. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol. 1999;106(2):445-54.

Fioretos T, Strömbeck B, Sandberg T, et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood. 1999;94(1):225-32.

Wattel E, Laï JL, Hebbar M, et al. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leukemia Res. 1993;17(11):921-6.

MacGrogan D, Kalakonda N, Alvarez S, et al. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. Genes, Chromosomes Cancer. 2004;41(3):203-13.

Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J ClinOncol.2011;29(18):2499-506.

Streubel B, Sauerland C, Heil G, et al. Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12. Br J Haematol. 1998;100(3):521-33.

Reindl C, Quentmeier H, Petropoulos K, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.Clin Cancer Res. 2009;15(7):2238-47.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.